Showing results (11-20 of 349) with videos related to
Sort By:
Pageof 35
BMJ Case Reports|October 6, 2017
Anti-PD-L1 therapy and the onset of diabetes mellitus with positive pancreatic autoantibodiesJennifer Way, Alexandra Drakaki, Andrew Drexler, et al.Clinics and Practice|January 8, 2019
Rapidly progressive neurologic decline and morbilliform rash presenting in a patient with lymphomaDean Ehrlich, Jennifer Phan, Gavin Hui, et al.Life (Basel, Switzerland)|March 25, 2022
Treatment Equity in the Immunotherapy Era: Options for Patients with Both Autoimmune Disease and GU CancersGavin Hui, Claire Drolen, Christopher A Hannigan, et al.Cureus|September 22, 2025
Unchecked Immunity to Unleashed Anarchy: A Case of Hemophagocytic Lymphohistiocytosis Following Combination Immune Checkpoint Inhibitor TherapySunil R Dommaraju, Dimitrios Stefanoudakis, Gavin Hui, et al.American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial CancerPetros Grivas, Alexandra Drakaki, Terence W Friedlander, et al.Transplantation Proceedings|October 20, 2019
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Metastatic Cancer Post Solid Organ Transplantation: A Case Report and Review of the LiteratureKarlton Wong, John Shen, Sarah D'Ambruoso, et al.Cancer Journal (Sudbury, Mass.)|July 23, 2013
Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeuticsAlexandra Bailey, David F McDermottCancer Journal (Sudbury, Mass.)|August 18, 2018
Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell CarcinomaXin Gao, David F McDermottAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedsideMatthew Weinstock, David F McDermottExpert Opinion on Investigational Drugs|December 16, 2014
Nivolumab for the treatment of cancerAnasuya Gunturi, David F McDermottPageof 35